Mitochondria and Vascular Health

Mitoquinol is one of the most researched mitochondria-targeted antioxidants out there, but what makes it different from regular CoQ10 — and why has so much of the clinical research focused specifically on vascular health? In this mini episode, naturopath Tyla breaks down the science behind mitoquinol, from its origins at the University of Otago to what the human trials are actually showing about blood vessel function as we age.

• Why mitochondrial dysfunction is considered a core hallmark of aging

• How oxidative stress and mitochondrial decline feed into each other — and why that matters for blood vessels

• The engineering behind mitoquinol: how it's built to actually reach the mitochondria, unlike standard CoQ10

• Key human trials, including the landmark 2018 Rossman study on endothelial function in older adults

• What the research shows for peripheral artery disease, blood pressure, and exercise performance

• Where the science is heading next, from frailty and cognition to postmenopausal vascular health and stroke recovery

Whether you're curious about mitoquinol specifically or want to understand the mitochondrial mechanisms behind vascular aging, this episode breaks down why targeted delivery is the whole story.

• Transcript

  Tyla (00:16) 

  Welcome back to the MidoPod. I'm Tyla I'm a qualified naturopath and I support our host Georgia with all things science communication. 

  And today I want to talk about something that sits right at the intersection of two things a lot of us really care about, which is healthy aging and heart and vascular health. So we're talking about mitoquinol, what it actually is, how it's different from the regular CoQ10 , you already know. 

  And why so much of the clinical research has landed specifically on vascular aging. So by the end of this episode, I want you to understand not just what mitoquinol is, but why mitochondria targeted delivery is really the whole story here. 

  Let's start at the beginning. So when we talk about aging, why are we even talking about mitochondria? So mitochondrial dysfunction is actually recognized as one of the twelve hallmarks of aging. And that's a big deal because it means that researchers can see this as a core driver of physiological changes we associate with getting older. Most people know that mitochondria are the powerhouse of the cell. But they do so much more than just make energy. 

  They're central to redox balance, cellular signaling, inflammation, and of course vascular function. As mitochondria become less efficient with age, our cells lose some of their resilience, and that shows up across a lot of different tissues. So, where does oxidative stress fit into this picture? Mitochondria naturally produce reactive oxygen species, or ROS, as a byproduct of energy production. 

  Now, at normal levels, ROS actually play a useful signaling role. But when production outpaces the cell's ability to manage it, ROS can damage proteins, lipids, and even mitochondrial DNA. And that damage can further impair mitochondrial function. So you get this cycle where oxidative stress and mitochondrial decline start to feed into one another. And that cycle is particularly relevant to blood vessels. 

  So healthy endothelial function, which is the lining of your blood vessels, Depends on mitochondria working properly to regulate vascular tone and blood flow. As mitochondrial oxidative stress rises with age, endothelial function tends to decline. And that's actually been shown directly in randomized placebo-controlled research in older adults. 

  So if mitochondrial oxidative stress is a big driver here, the obvious next question is can we target it directly? And that's exactly the question that led to mitoquinol. 

  So let's get into what mitoquinol really is and how it's different from the CoQ10 ten people already know. 

  So, mitoquinol is a mitochondria-targeted antioxidant developed from COQ10. COC10 itself is essential for energy production and antioxidant defense inside the mitochondria. But the catch is that regular COQ10 supplements aren't actually built to get there efficiently. A lot of people assume that they're taking a COQ10, so it's just going where it needs to go, 

  But CoQ10 is a large fat-soluble molecule. It's absorbed inefficiently to begin with, usually needing dietary fat just to improve its bioavailability. And even once it's absorbed, mitochondrial membranes are highly selective. So only a small fraction of what you actually take ends up where it needs to go. So the question isn't how much reaches your bloodstream, it's how much reaches the mitochondria themselves. 

  And that's the exact problem mitoquinol was engineered to solve. Now we love the history here because this story starts right here in New Zealand. Back in the 1990s, professors Mike Murphy and Robin Smith, who were working at the University of Otago, set out to figure out why conventional antioxidants weren't reaching the mitochondria. 

  So their solution was to modify the CoQ10 molecule by shortening its carbon chain and attaching a lipophilic positive charge. That charge let the molecule cross the biological membranes more efficiently and get pulled towards the strong negative charge inside the mitochondria. Now this compound became MitoQ or Mitoquinol. 

  So that's the mechanism. It's a positive charge getting drawn towards the negative charge inside the mitochondria. And it's built from three parts: an antioxidant head group from CoQ10, a shortened carbon chain for easier membrane crossing, and a positively charged group called triphenylphosphonium, or TPP. 

  So that TPP tag is really the delivery address. It's what accumulates specifically inside mitochondria at concentrations well above what you would see with non-targeted antioxidants. So once it's inside, what is it actually doing? So it anchors in the inner mitochondrial membrane, right where oxidative phosphorylation is happening. 

  And it's where ROS are generated. So from there it can interact directly with reactive oxygen species. And what's really impressive is that mitoquinol can actually be recycled back to its active form. So a single molecule can repeatedly participate in antioxidant activity rather than just working once. 

  So let's get into the human research because this is where it gets pretty interesting. So the foundational study here is the Rossmann and Colleagues study published in Hypertension in 2018. 

  This was a randomized placebo-controlled crossover trial in 20 healthy older adults aged from 60 to 79. Now these adults had impaired endothelial function going on and they did six weeks of mitoquinol supplementation. 

  And what they found was a marked improvement in the artery's ability to dilate, plus benefits to aortic health and lipid metabolism. Now, what made this trial significant is that it was among the first to take findings that had only really been shown in animal models and translate them into human evidence. 

  showing that a mitochondria-targeted antioxidant could meaningfully support vascular function just by lowering oxidative stress at the cellular source. And there was a follow-up digging into why that improvement happened too. 

  A later mechanistic analysis using plasma from the same trial linked the improvement to reduced circulating oxidized LDL and lower oxidative stress in endothelial cells. 

  And the research has moved beyond healthy older adults into specific conditions as well. There's a trial on peripheral artery disease or PAD that looked at whether a single 80 milligram dose of mitoquinol could improve claudication onset or leg pain during walking, as well as maximal walking time and leg artery dilation. 

  And on blood pressure specifically, there's a randomized control trial in hypertensive adults that found that mitoquinol reduced left ventricular mass, improved cardiac structural measures, and lowered markers of oxidative stress and inflammation. And what was interesting was that the effects were strongest when supplementation was combined with exercise training. 

  Now this synergistic effect is really meaningful for us because It's not just take this molecule instead of exercising. It's really this and exercise together is really powerful. And that pattern shows up more broadly. 

  So a 2024 systematic review and meta-analysis found that mitoquinol reliably reduces exercise-induced oxidative damage and it may specifically help exercise tolerance in people with PAD. 

  Now what's interesting is that it didn't appear to boost aerobic performance in already healthy populations. So the picture that's emerging is that these mitochondria-targeted antioxidants seem to do the most work in people where oxidative stress and vascular dysfunction are already elevated. And that benefit may be amplified alongside things like regular physical activity. 

  so in these studies it seems to be more about supporting resilience where there's already a strain on the system. 

  So where is the research heading from here? there's a real shift happening towards larger, longer term, more clinically applied trials. So there's the mitofrail trial at UConn Health looking at effects on vascular function, oxidative stress. 

  Mobility and cognitive performance in frail and non-frail older adults. There's also the study at Colorado State University evaluating daily mitoquinol against placebo over three months, specifically looking at brain artery function in postmenopausal women. On the disease side, researchers at the University of Nebraska 

  are running a trial on walking ability, daily activity, quality of life, and calf muscle measures in people with PAD and intermittent claudication, which builds directly on those earlier PAD findings over a longer time frame, There's also work underway 

  Combining mitoquinol with ischemic conditioning for vascular health after stroke and research in microvascular function in healthy adults. 

  Just something with flagging is that a lot of these are still recruiting or not yet recruiting. So we're talking about where the science is heading, not settled findings at this stage. But the direction is clear that the question is moving from can this reduce oxidative stress to does this translate into meaningful differences in mobility, independence, and cardiovascular resilience As people age, which is really exciting. 

  So if you take away just one thing from this episode, I want it to be that mitochondrial targeting is an entire mechanism in itself. 

  The reason mitoquinol behaves differently from standard CoQ10 in the body comes down to that TPP delivery system, getting it where oxidative stress actually originates. And the vascular research we've walked through today is a direct result of that targeting. 

  So thank you so much for listening. If you want to dig into any of the studies we mentioned today, you'll find them linked in the show notes, along with a link to a full list of active and completed mitoquinol clinical trials on the MCRP research page. 

  As always, this episode is for educational purposes only, so please talk to your healthcare provider before making any changes to your supplement routine. And we'll see you next time on the MidoPod.